La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PaxMedica a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PaxMedica..

PaxMedica (OTC:PXMD) Azioni, Catena delle Opzioni

PaxMedica

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

PaxMedica Inc

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Wednesday.
The Dow traded up 3.17% to 43,561.18 while the NASDAQ rose 2.23% to 18,849.87. The S&amp;P 500 also rose, gaining, 1.95% to 5,895.66.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41774936/how-to-earn-500-a-month-from-qualcomm-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 5.3% on Tuesday.
In trading on Tuesday, real estate shares fell by 3.2%.
Top Headline
Shares of CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) jumped more than 10% on Wednesday after the company reported third-quarter results.
The company reported third-quarter sales of $95.43 billion, beating the consensus of $92.75 billion. Total revenues increased 6.3%, primarily driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the Health Services segment.
Adjusted EPS of $1.09 (inline with preliminary guidance of $1.05-$1.10) decreased from $2.21 in the prior year, missing the consensus of $1.53.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 31% to $7.14 following upbeat quarterly results.</li>
<li>Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) got a boost, surging 100% to $8.41 after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.</li>
<li>Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares were also up, gaining 24% to $7.15 following strong quarterly results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares dropped 42% to $4.12. Shares of solar stocks traded lower following Donald Trump&#8217;s presidential election victory.</li>
<li>Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) were down 39% to $8.05 after the company announced the pricing of $9.15 million private placement.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) was down, falling 38% to $18.30 after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $72.53 while gold traded down 2.4% at $2,683.70.
Silver traded down 3.9% to $31.505 on Wednesday, while copper fell 4.5% to $4.2755.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.61%, Germany's DAX dipped 1.23% and France's CAC 40 fell 0.85%. Spain's IBEX 35 Index fell 3.14%, while London's FTSE 100 fell 0.08%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 2.61%, Hong Kong's Hang Seng Index falling 2.23%, China's Shanghai Composite Index falling 0.09% and India's BSE Sensex gaining 1.13%.
Economics
<ul>
<li>U.S. mortgage applications fell by 10.8% from the previous week in the week ended Nov. 1.</li>
<li>U.S. crude oil inventories increased by 2.149 million barrels in the week ended Nov. 1, compared to market estimates of a 1.8 million gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41773566/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

CTKB

NOVA

PACS

SONN

TMCI

ZCAR

Gold Down Over 2%; CVS Health Shares Jump After Q3 Results

Canaccord Genuity analyst Richard Close maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Buy and lowers the price target from $14 to $13.

Price Target

Analyst Ratings

AHCO

Canaccord Genuity Maintains Buy on AdaptHealth, Lowers Price Target to $13

Roth MKM analyst Matt Koranda reiterates Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) with a Buy and raises the price target from $29 to $35.

Reiteration

RVLV

Roth MKM Reiterates Buy on Revolve Gr, Raises Price Target to $35

TD Cowen analyst Phil Nadeau maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $55 to $65.

RYTM

TD Cowen Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $65

WIIM

CDXC

ChromaDex shares are trading higher after Roth MKM maintained a Buy rating on the stock and raised its price target from $6 to $8.

The <a href="https://www.benzinga.com/personal-finance/24/10/41438273/can-you-guess-how-much-money-the-fat-fire-movement-says-you-need-to-retire-early-heres-a-hint-it">Financial Independence Retire Early (FIRE) movement</a> has captured attention across generations. It promises a life where financial independence allows you to retire early and focus on what you love. But not everyone is a fan. Financial expert Suze Orman has been famously critical of FIRE, labeling it dangerous for those without substantial wealth.
Don't Miss:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
The FIRE movement is rooted in two main ideas: extreme saving and early retirement. By saving 50% or more of their income, followers of FIRE aim to accumulate a large retirement fund to live off investment returns, <a href="https://www.benzinga.com/personal-finance/24/08/40491347/47-year-old-unmotivated-multimillionaire-doctor-asks-dave-ramsey-retire-now-or-work-13-more-year">often before age 40</a>. While some adhere to "lean FIRE," maintaining a modest lifestyle with a smaller retirement fund, others pursue "fat FIRE," accumulating more to enjoy a comfortable lifestyle. The concept has gained significant traction, especially among millennials seeking alternatives to traditional career paths.
However, orman believes that FIRE oversimplifies the financial risks involved. In a 2018 interview on the Afford Anything podcast, she warned that even a seemingly substantial nest egg, like $2 million, might not be enough.&nbsp;
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
"$2 million is nothing. It's nothing. It's pennies in today's world, to tell you the truth," she stated, expressing her concern that even millions could fall short in the face of life's uncertainties. Orman explained, "If a catastrophe happens … what are you going to do? You are going to burn up alive." For her, retirement requires far more planning than what many anticipate.&nbsp;
Orman's perspective is deeply rooted in the belief that financial independence requires a far larger cushion than most people realize. She even made a clear distinction between <a href="https://www.benzinga.com/personal-finance/24/09/40711869/how-rich-are-you-heres-the-net-worth-that-defines-upper-middle-and-lower-class">average savers and the ultra-wealthy</a>. "If you have $20 [million], $40 [million], $50 [million] or $100 million, be like me, okay," Orman said. "If you have that kind of money … and want to retire, fine." But for the vast majority, she warns, retiring without that level of wealth is risky and could lead to financial disaster. Her message was simple: early retirement might not be safe unless you&#8217;re extraordinarily wealthy.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
Orman's core criticism revolves around FIRE's approach to risk. She points out that unexpected expenses – like major health issues or long-term care – can devastate savings, especially for those who retire decades early. Orman illustrated the potential costs by suggesting that supporting a disabled family member could easily require $250,000 a year. Coupled with living expenses, she argues that maintaining a safe, sustainable retirement could require as much as $10 million in savings to ensure a comfortable life through any storms that might come.
With inflation steadily increasing, her projections from 2018 seem even more relevant now. Living costs, health care expenses and potential tax hikes have all risen, making financial independence harder to achieve than just a few years ago.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Ultimately Orman advises that the risk of retiring early outweighs the reward if you're not <a href="https://www.benzinga.com/personal-finance/24/10/41125098/suze-orman-says-the-personal-finance-of-americans-is-really-really-bad-even-though-the-stock-mar">financially equipped for unforeseen hardships</a>. "If you don't have at least $5 million or $10 million, don't retire early," she emphasized. In her view, early retirement might work for those with vast resources – people who, like herself, have tens of millions to safeguard against all possibilities – but for everyone else, it's a path that could lead to financial ruin rather than freedom.
So, is FIRE worth pursuing? It depends on your risk tolerance, lifestyle goals and financial resilience.&nbsp;
The <a href="https://www.benzinga.com/personal-finance/24/09/40964924/most-people-expect-to-retire-at-67-but-56-retire-sooner-can-you-guess-the-actual-average-retirem">average retirement age</a> is 62, but Orman strongly advocates working longer and <a href="https://www.benzinga.com/personal-finance/24/05/39064579/suze-orman-says-70-is-the-new-retirement-age-but-is-she-right">delaying Social Security until 70</a> to maximize those benefits. <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">Consulting with a financial advisor could be one of the smartest moves</a> for anyone eyeing an early exit from work. An advisor can help you stress-test your retirement plan, look at real-life scenarios and ensure you're prepared for whatever may come.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a></li>
</ul>

Personal Finance

Suze Orman Says If You're Rich 'Like Her' Then You Can Retire Early – But If You Only Have $2 Million Saved: 'You'll Burn Up Alive'

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $72 to $70.

BRKR

TD Cowen Maintains Hold on Bruker, Lowers Price Target to $70

Roth MKM analyst Chip Moore maintains Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) with a Buy and lowers the price target from $84 to $70.

Roth MKM Maintains Buy on Hyster Yale, Lowers Price Target to $70

Honda Motor Company, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) shares are trading lower on Wednesday following a decline in the first-half profit and reduced <a href="https://global.honda/en/investors/library/documents/main/00/teaserItems3/00/linkList/00/link/FYE202503_2Q_financial_presentation_e_1.pdf" target="_blank" rel="noreferrer noopener">annual </a>profit forecast.
The company reported the first half of FY24 revenue growth of 12.4% year over year 10.798 trillion yen ($69.9 billion), while profits declined 19.7% to 494.6 billion Yen ($3.20 billion).
Automobile consolidated unit sales rose by 64,000 units, driven by strong ICE/HEV sales and the full-scale launch of <a target="_blank" href="https://global.honda/en/investors/library/documents/main/00/teaserItems3/00/linkList/03/link/FYE202503_2Q_financial_presentation_script_e.pdf" rel="noreferrer noopener">EVs </a>in North America.
However, group unit sales fell by 155,000 units, primarily due to lower sales in China.
In the motorcycle business, global sales remained robust, reaching a cumulative total of 10 million units by the end of the second quarter.
Operating profit rose 6.6% to 742.6 billion yen, with a margin of 6.9% (vs<a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">. 7.2% in the first half of FY23)</a>.
Additionally, a resolution was made at the company&#8217;s board meeting to repurchase company shares, up to 100 billion yen.
Outlook: For FY25, the company reduced profit for the year attributable to owners of the parent by 50 billion yen to 950 billion yen due to lower equity method profit from reduced sales in China and decreased profit in <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Honda&#8217;s affiliates in Japan</a>.
On the other hand, the company raised the sales revenue forecast by 700 billion yen to 21.000 trillion yen.
Meanwhile, Honda reiterated its FY25 operating profit forecast at 1.420 trillion yen.
Price Action: HMC shares are down 9.72% at $27.36 at the last check Wednesday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41699452/hondas-pickup-beats-tesla-cybertruck-as-most-american-made-truck" target="_blank" rel="noreferrer noopener">Honda&#8217;s Pickup Beats Tesla Cybertruck As Most American Made Truck</a></li>
</ul>

Large Cap

Movers

Honda Reports 19.7% Profit Decline in H1, Lowers Annual Profit Forecast Amid China Sales Slump

TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Hold and lowers the price target from $132 to $122.

BNTX

TD Cowen Maintains Hold on BioNTech, Lowers Price Target to $122

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $95 to $75.

EXAS

Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $75

Donald Trump has been elected as the 47th president of the U.S., and the future of <a href="https://www.benzinga.com/electric-vehicles">the electric vehicle (EV) industry</a> is uncertain. 
Here's a look at how the president-elect&#8217;s policy changes could affect<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41755274/trump-win-could-hinder-tech-ev-sector-growth-slow-the-pace-of-ai-revolution-analyst"> EV makers in the US. </a>
Trump's EV Views: Trump, who <a href="https://www.benzinga.com/markets/equities/24/10/41562048/leonardo-dicaprio-backs-harris-says-trump-continues-to-deny-the-facts-on-climate">has denied climate change</a>, as largely condemned EVs. He claims they will cost autoworkers' jobs as factories make the shift to electric vehicles. He has also said EVs are<a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor"> being forced </a>on consumers through unfair regulations. 
"I will end the electric vehicle mandate on day one, thereby saving the auto industry from complete obliteration which is happening right now and saving US customers thousands and thousands of dollars per car," Trump said in a speech at the Republican National Convention in July.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/11/41754367/china-escalates-trade-dispute-lodges-complaint-with-wto-over-european-ev-tariffs">China Escalates Trade Dispute, Lodges Complaint With WTO Over European EV Tariffs</a>
Trump has also said he plans <a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor">to eliminate</a> many vehicle emissions standards under the Environmental Protection Agency as well as many EV incentives included in the Biden administration's Inflation Reduction Act (IRA).
Analysts Weigh In: Wedbush analysts, including Dan Ives, see <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41755274/trump-win-could-hinder-tech-ev-sector-growth-slow-the-pace-of-ai-revolution-analyst">trouble ahead</a> for the EV industry.&nbsp;
&#8220;We believe a Trump presidency would be an overall negative for the EV industry as likely the EV rebates/tax incentives get pulled, however for Tesla we see this as a potential positive with some caveats,&#8221; the Wedbush analysts wrote.&nbsp;
The analysts pointed to Tesla, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) profitability, along with the company's size and scale, as advantages over its competitors who may struggle after losing rebates and tax incentives. Wedbush also sees Tesla benefiting from higher import fees on Chinese EVs under a Trump administration. 
&#8220;Higher China tariffs that would continue to push away cheaper EV players (BYD, Nio, etc.) from flooding the US market over the coming years,&#8221; Wedbush wrote.&nbsp;
Tesla CEO Elon Musk, who campaigned heavily <a href="https://www.benzinga.com/news/24/11/41766808/mark-cuban-congratulates-trump-musk-before-the-election-is-called-says-they-won-fair-and-square">for the GOP leader</a>, acknowledged that a Trump presidency would likely mean the end of EV subsidies and tax credits during Tesla's second-quarter earnings call. 
The impact would be slight for Tesla and devastating for its competitors, Musk said.
"But long term probably actually helps Tesla, would be my guess, yes," Musk said.&nbsp;
The Big 3: Legacy automakers, General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) are struggling as they transition from traditional combustion engines to EVs. 
The Big 3 automakers have recently announced they will delay investments and other plans related to the production of EVs amid <a href="https://www.benzinga.com/news/24/11/41737069/ford-ev-sales-drop-over-8-in-october-as-demand-for-f-150-lightning-slows-down">waning demand </a>from consumers. 
What's Next: It remains to be seen what measures will be repealed under a Trump administration and how each automaker will be affected. However, investors seem to agree with Tesla analysts that Trump's second term is a positive catalyst for the EV giant. Tesla shares are soaring 12.8% higher at $283.49 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Image: Shutterstock

Politics

STLA

TSLA

What Does Trump's Victory Mean For EV Giant Tesla And The Big 3 Automakers?

Roth MKM analyst Bill Kirk maintains Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Neutral and lowers the price target from $20 to $16.

Roth MKM Maintains Neutral on Grocery Outlet Holding, Lowers Price Target to $16

Roth MKM analyst Jason Wittes reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Buy and maintains $100 price target.

GMED

Roth MKM Reiterates Buy on Globus Medical, Maintains $100 Price Target

For Kevin O&#8217;Leary, the business world is black and white: you either succeed or fail. "Business is binary. There are winners and losers. You either make money or you don't," he says.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Business is binary. There are winners and losers. You either make money or you lose it. If you want to succeed in business you have to work 25hrs a day because there's someone across the world who will kick your a&#x2A;s if you don't. <a href="https://t.co/mRURSOPoz8">pic.twitter.com/mRURSOPoz8</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1853432280565330223?ref_src=twsrc%5Etfw">November 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
O&#8217;Leary, famously known as &#8220;Mr. Wonderful&#8221; on Shark Tank, loves sharing his formula for success, especially with young entrepreneurs. His advice is direct: if you&#8217;re in your 20s and trying to build a business, forget about having a work-life balance. The competition is just too intense.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
&#8220;You're competing with people in Mumbai or Shanghai who are <a href="https://www.benzinga.com/startups/24/10/41231722/kevin-oleary-says-theres-no-worklife-balance-for-new-entrepreneurs-as-guys-in-mumbai-or-shanghai-wor">willing to work 24 hours a day</a>, eight days a week,&#8221; O&#8217;Leary once said. In his view, you&#8217;re at risk of being left behind unless you&#8217;re ready to put in those kinds of hours. He even goes so far as to say that to be successful, you need to work relentlessly or as he puts it, &#8220;25 hours a day.&#8221;&nbsp;
Working around the clock sounds extreme to most people, but O&#8217;Leary knows the importance of laying a strong foundation in the early stages of your career. When you're young, you have the time and energy to make sacrifices because &#8220;In your 20s, you can afford the time, the focus and all the stress that comes with building something from the ground up. You should start thinking about taking some time off only after establishing that foundation.&#8221;
Trending: With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a>
O&#8217;Leary knows firsthand how frustrating it can be to slow down. After selling The Learning Company, he was <a href="https://www.benzinga.com/startups/24/09/40776473/it-was-boring-kevin-oleary-explored-every-beach-on-earth-after-he-first-got-rich-but-the-highs-and-l?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=site&amp;nid=41231722">tied up in a noncompete agreement</a> that kept him out of the software industry for three years. What many might see as a well-earned break was stifling for O&#8217;Leary, who said he felt &#8220;stale&#8221; without the ability to work. He quickly understood that his feeling of purpose depended on his ability to continue building businesses.
This relentless pursuit of success is also reflected in his approach to investing. O&#8217;Leary has one rule regarding money: always invest in information. &#8220;If you make decisions without relevant information, I guarantee you, you will lose money 100% of the time,&#8221; he said.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Each day, <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/01/30554489/kevin-oleary-reveals-his-secret-to-success-what-he-does-every-day-to-avoid-losing-money-">O&#8217;Leary starts his mornings early</a>, dedicating an hour to consuming news from various sources – early broadcasts from Europe and Asia or academic and financial research.
For O&#8217;Leary, the lesson is straightforward: Sacrifice is necessary for success. To succeed as an entrepreneur, you must be prepared to work harder and longer hours than your competitors, stay informed and persevere.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
</ul>

Startups

Kevin O'Leary Claims 'You Have To Work 25 Hours A Day.' For Him, Business Is Simple: 'You Either Make Money Or You Don't'

CRCT

Cricut shares are trading lower after the company cut its price target on the stock from $6.5 to $5.75.

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $6 to $8.

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $8

Dine Brands Global shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Financials sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$250.00</td>
<td>$107.0K</td>
<td>4.1K</td>
<td>12.4K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$72.50</td>
<td>$98.4K</td>
<td>3.7K</td>
<td>7.4K</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$180.00</td>
<td>$1.4 million</td>
<td>654</td>
<td>5.5K</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$135.00</td>
<td>$70.0K</td>
<td>10</td>
<td>3.2K</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$29.00</td>
<td>$29.9K</td>
<td>233</td>
<td>2.1K</td>
</tr>
<tr>
<td>KKR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$100.00</td>
<td>$131.5K</td>
<td>3.4K</td>
<td>260</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1000.00</td>
<td>$407.5K</td>
<td>4</td>
<td>100</td>
</tr>
<tr>
<td>RJF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$170.00</td>
<td>$40.0K</td>
<td>16</td>
<td>100</td>
</tr>
<tr>
<td>TFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$35.00</td>
<td>$94.5K</td>
<td>2.0K</td>
<td>80</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$500.00</td>
<td>$34.7K</td>
<td>1.6K</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding COIN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 8, 2024. Parties traded 214 contract(s) at a $250.00 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $107.0K, with a price of $500.0 per contract. There were 4138 open contracts at this strike prior to today, and today 12429 contract(s) were bought and sold. 
• Regarding C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on December 20, 2024. Parties traded 639 contract(s) at a $72.50 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $98.4K, with a price of $154.0 per contract. There were 3795 open contracts at this strike prior to today, and today 7475 contract(s) were bought and sold. 
• For BX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), we notice a call option sweep that happens to be bullish, expiring in 135 day(s) on March 21, 2025. This event was a transfer of 1240 contract(s) at a $180.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $1.4 million, with a price of $1150.0 per contract. There were 654 open contracts at this strike prior to today, and today 5551 contract(s) were bought and sold. 
• For MS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), we notice a put option sweep that happens to be bullish, expiring in 72 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $135.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $70.0K, with a price of $700.0 per contract. There were 10 open contracts at this strike prior to today, and today 3256 contract(s) were bought and sold. 
• Regarding HOOD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), we observe a put option sweep with bearish sentiment. It expires in 72 day(s) on January 17, 2025. Parties traded 113 contract(s) at a $29.00 strike. This particular put needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $29.9K, with a price of $265.0 per contract. There were 233 open contracts at this strike prior to today, and today 2178 contract(s) were bought and sold. 
• For KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), we notice a call option sweep that happens to be bearish, expiring in 317 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $131.5K, with a price of $5720.0 per contract. There were 3464 open contracts at this strike prior to today, and today 260 contract(s) were bought and sold. 
• Regarding BLK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), we observe a put option trade with bearish sentiment. It expires in 436 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $1000.00 strike. The total cost received by the writing party (or parties) was $407.5K, with a price of $8150.0 per contract. There were 4 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding RJF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), we observe a call option trade with bearish sentiment. It expires in 191 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $170.00 strike. The total cost received by the writing party (or parties) was $40.0K, with a price of $800.0 per contract. There were 16 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For TFC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>), we notice a call option trade that happens to be bullish, expiring in 226 day(s) on June 20, 2025. This event was a transfer of 80 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $94.5K, with a price of $1182.0 per contract. There were 2070 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding MA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), we observe a call option trade with bearish sentiment. It expires in 72 day(s) on January 17, 2025. Parties traded 11 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $34.7K, with a price of $3162.0 per contract. There were 1606 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

COIN

HOOD

10 Financials Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$300.00</td>
<td>$41.2K</td>
<td>34.6K</td>
<td>109.6K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$210.00</td>
<td>$37.6K</td>
<td>46.8K</td>
<td>38.8K</td>
</tr>
<tr>
<td>DHI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$170.00</td>
<td>$49.4K</td>
<td>11.4K</td>
<td>9.0K</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.00</td>
<td>$353.4K</td>
<td>2.8K</td>
<td>2.3K</td>
</tr>
<tr>
<td>DKS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$195.00</td>
<td>$50.1K</td>
<td>828</td>
<td>1.3K</td>
</tr>
<tr>
<td>PRKS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$55.00</td>
<td>$38.8K</td>
<td>181</td>
<td>1.1K</td>
</tr>
<tr>
<td>EWCZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.50</td>
<td>$33.6K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>W</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$42.00</td>
<td>$28.5K</td>
<td>1.0K</td>
<td>674</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$150.00</td>
<td>$60.4K</td>
<td>183</td>
<td>639</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$93.00</td>
<td>$48.1K</td>
<td>486</td>
<td>377</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 8, 2024. This event was a transfer of 200 contract(s) at a $300.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.2K, with a price of $206.0 per contract. There were 34669 open contracts at this strike prior to today, and today 109633 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on November 15, 2024. This event was a transfer of 200 contract(s) at a $210.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $188.0 per contract. There were 46810 open contracts at this strike prior to today, and today 38848 contract(s) were bought and sold. 
• Regarding DHI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), we observe a call option sweep with bullish sentiment. It expires in 9 day(s) on November 15, 2024. Parties traded 494 contract(s) at a $170.00 strike. This particular call needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $49.4K, with a price of $100.0 per contract. There were 11450 open contracts at this strike prior to today, and today 9078 contract(s) were bought and sold. 
• Regarding MBLY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), we observe a call option trade with bearish sentiment. It expires in 72 day(s) on January 17, 2025. Parties traded 789 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $353.4K, with a price of $448.0 per contract. There were 2854 open contracts at this strike prior to today, and today 2332 contract(s) were bought and sold. 
• Regarding DKS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), we observe a put option trade with bearish sentiment. It expires in 72 day(s) on January 17, 2025. Parties traded 30 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $50.1K, with a price of $1670.0 per contract. There were 828 open contracts at this strike prior to today, and today 1352 contract(s) were bought and sold. 
• For PRKS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>), we notice a call option sweep that happens to be bearish, expiring in 44 day(s) on December 20, 2024. This event was a transfer of 105 contract(s) at a $55.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $38.8K, with a price of $370.0 per contract. There were 181 open contracts at this strike prior to today, and today 1108 contract(s) were bought and sold. 
• Regarding EWCZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>), we observe a call option sweep with bearish sentiment. It expires in 44 day(s) on December 20, 2024. Parties traded 369 contract(s) at a $7.50 strike. This particular call needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $33.6K, with a price of $90.0 per contract. There were 2181 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• Regarding W (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on November 15, 2024. Parties traded 76 contract(s) at a $42.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $375.0 per contract. There were 1033 open contracts at this strike prior to today, and today 674 contract(s) were bought and sold. 
• Regarding TOL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>), we observe a put option trade with bullish sentiment. It expires in 135 day(s) on March 21, 2025. Parties traded 42 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $1440.0 per contract. There were 183 open contracts at this strike prior to today, and today 639 contract(s) were bought and sold. 
• Regarding BBY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), we observe a put option sweep with bullish sentiment. It expires in 2 day(s) on November 8, 2024. Parties traded 125 contract(s) at a $93.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $385.0 per contract. There were 486 open contracts at this strike prior to today, and today 377 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

EWCZ

MBLY

PRKS

10 Consumer Discretionary Stocks Whale Activity In Today's Session

PaxMedica, Inc. (PXMD) has shared an update. PaxMedica, Inc. has released an updated corporate slide presentation on its website for use in discuss...

PaxMedica Releases Updated Investor Presentation Online

PaxMedica shares soar 125% post-market on drug update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Friday is here and we&rsquo;re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!



Moving stocks this morning are earnings reports, stakeholder updates, drug development news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing close to 82% after hitting a <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">key milestone in drug development</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are soaring more than 61% alongside heavy pre-market trading.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) stock is surging over 36% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230226&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=e948601bd73c48c35f25d9d7dd224e92&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-11">following a stakeholder update</a>.</li>



<li>NextPlat (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxpl-stock-quote/">NXPL</a>) shares are rising 32% alongside a <a href="https://www.nasdaq.com/press-release/nextplat-reports-consolidated-year-end-2023-results-with-increased-revenues-of-%2437.8">positive 2023 earnings report</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is increasing more than 25% with strong early morning trading.</li>



<li>Beneficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/">BENF</a>) shares are gaining over 25% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230412&amp;type=PDF&amp;symbol=BENF&amp;cdn=eb254668ceab70d3f25ad97304b464e9&amp;companyName=Beneficient&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-11">a stakeholder update</a>.</li>



<li>NRX Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrxp-stock-quote/">NRXP</a>) stock is heading more than 18% higher <a href="https://www.nasdaq.com/press-release/nrxs-nasdaq%3a-nrxp-nmda-modification-therapy-and-its-multiple-applications-from-mental">on therapy news</a>.</li>



<li>Lyell Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/lyel-stock-quote/">LYEL</a>) shares are jumping over 15% this morning.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock is climbing more than 14% on <a href="https://www.nasdaq.com/press-release/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure">positive drug news</a>.</li>



<li>OncoCyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/">OCX</a>) shares are up over 14% with its <a href="https://ng.investing.com/news/stock-market-news/oncocyte-reports-full-year-2023-financial-results-93CH-1298708">Q4 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Motus GI (NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is plummeting more than 35% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">on a delisting warning</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are diving 17% despite a lack of news today.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is retreating over 15% <a href="https://investorplace.com/2024/04/why-is-rent-the-runway-rent-stock-up-30-today/">after rallying yesterday</a>.</li>



<li>Monogram Orthopaedics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrm-stock-quote/">MGRM</a>) shares are tumbling more than 13% as it <a href="https://www.nasdaq.com/press-release/monogram-accepted-to-nvidia-inception-program-2024-04-11">also jumped higher yesterday</a>.</li>



<li>Rallybio (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlyb-stock-quote/">RLYB</a>) stock is pulling back over 11% after a <a href="https://investorplace.com/2024/04/why-is-rallybio-rlyb-stock-up-93-today/">major rally on Thursday</a>.</li>



<li>Applied Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) shares are falling more than 11% with its <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">fiscal Q3 2024 earnings report</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is taking an over 10% beating without any clear news this morning.</li>



<li>MOGU (NYSE:<a href="https://investorplace.com/stock-quotes/mogu-stock-quote/">MOGU</a>) shares are decreasing more than 10% with no obvious news to report.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) stock is dropping over 10% <a href="https://investorplace.com/2024/04/why-is-marin-software-mrin-stock-up-62-today/">after rallying recently</a>.</li>



<li>GCT Semiconductor (NYSE:<a href="https://investorplace.com/stock-quotes/gcts-stock-quote/">GCTS</a>) shares close out our pre-market stock movers down more than 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">reached a key milestone</a> in drug development.



The big news here is the company securing three pivotal registration/validation batches of PAX-101. The company says that this is a key milestone in its plans for a New Drug Application (NDA) set for Q4 2024.



Investors are celebrating this news as it puts PAX-101 one step closer to approval from the Food and Drug Administration&nbsp;(FDA). If approved, it would be the first first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis.



<h2>What&rsquo;s Next for PXMD Stock?</h2>



Howard Weisman, chairman and CEO of&nbsp;PaxMedica, said the following about the company&rsquo;s next plan for PAX-101.




&ldquo;The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with Autism Spectrum Disorder. With this important manufacturing milestone completed, we have removed a major impediment to testing PAX-101 as a treatment for the core symptoms of Autism Spectrum Disorder.&rdquo;




All of this news brings with it heavy trading of PXMD stock this morning. That has more than 5 million shares changing hands as of this writing. That&rsquo;s quite the leap over its daily average trading volume of about 240,000 shares.



PXMD stock is up 92.7% as of Friday morning.



There are more stock market stories traders need to know about on Friday!



Luckily, we have all of the hottest stock market news ready to go today! That starts with our biggest pre-market stock movers this morning while also catching investors up on yesterday&rsquo;s news. You can dive into all of that at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>



<li><a href="https://investorplace.com/2024/04/cantor-fitzgerald-just-raised-its-rating-on-soundhound-ai-soun-stock/">Cantor Fitzgerald Just Raised Its Rating on SoundHound AI (SOUN) Stock</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is PaxMedica (PXMD) Stock Up 93% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is heading higher on Friday alongside heavy pre-market trading.



Investors will note that this movement comes after the company <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318229974&amp;type=PDF&amp;symbol=ALLR&amp;cdn=994a98b62336e93eb05e904c271966d1&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=424B5&amp;formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&amp;dateFiled=2024-04-11">announced a prospectus supplement</a>. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.



Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is eligible to sell $1,015,290 more.



<h2>ALLR Stock Movement Today</h2>



The heavy pre-market trading has more than 2.8 million shares of the clinical-stage biopharmaceutical company&rsquo;s stock changing hands. That&rsquo;s well above its daily average trading volume of about 59,000 shares.



Investors will also note that ALLR stock is up 41.3% as of Friday morning. Even so, the shares closed out Thursday down 78.9% since the start of the year.



Another thing to note is that ALLR is a penny stock. This comes from its low daily average trading volume, prior closing price of $2.30 per share and market capitalization of only $1.0821.082. All of these make it a risky investment.



There are even more of the most recent stock market stories traders will want to read about today below!



We are offering all of the hottest stock market news that investors need to know about on Friday! Among that is what has shares of PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>
</ul>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is falling on Friday following a warning that the medical technology company is in danger of being delisted.



Motus GI <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">got a delisting notice</a> from the Listing Qualifications Staff of the Nasdaq Exchange on April 5. In that notice, the company was warned about a potential delisting due to its low shares price.



Shares of MOTS stock have been trading for less than $1 each for over 30 business days. That has the company not complying with the minimum bid to remain listed on the exchange.



On that same note, Motus GI has enacted reverse stock splits with a ratio of 250 shares or more to one over the last year. That makes it ineligible for a compliance period to regain the $1 minimum bid.



<h2>What This Means for MOTS Stock</h2>



Motus GI has until today to request a hearing with the Nasdaq Exchange to try and avoid delisting. However, the company doesn&rsquo;t believe it can regain compliance and is choosing not to seek a hearing.



As a result, shares of MOTS stock will stop trading on the Nasdaq Exchange when markets open on Tuesday. This will result in its shares switching over to the OTC Pink Market of the OTCMarkets. It intends to apply for listing on the OTCQB.



Finally, Motus GI says it is exploring a range of strategic options. Its doing so to maximize shareholder value while speeding up the commercialization of its Pure-Vu System.



MOTS stock is down 37.1% as of Friday morning.



There are more stock market stories traders are going to want to read about!



Fortunately, we have a full list of stock market happenings worth reading on Friday! A few examples include what&rsquo;s sending shares of Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock higher, as well as the biggest pre-market stock movers this morning. All of that info is available below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Motus GI (MOTS) Stock Down 37% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Applied Digital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) stock is falling on Friday following the release of the data center company&rsquo;s earnings report for its fiscal third quarter of 2024.



The bad news for APLD stockholders starts with the company&rsquo;s <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">adjusted earnings per share of -24 cents</a>. That&rsquo;s much worse than the -7 cents per share that Wall Street was expecting. It&rsquo;s also a significant setback compared to the -1 cent per share from the same period of the year prior.



Also not helping matters is Applied Digital&rsquo;s revenue of $43.35 million in fiscal Q3 2024. That&rsquo;s another miss next to analysts&rsquo; revenue estimate of $51.92 million. This is despite it increasing 208% year-over-year from $14.09 million.



Wes Cummins, chairman and CEO of Applied Digital, said this in the earnings report.




&ldquo;During the quarter, Applied Digital encountered several challenges that impacted our financial performance due to facility power outages in our datacenter hosting business. Despite these short-term setbacks, we made significant progress with our key growth initiatives in the development of our Cloud Services business and the establishment of our special purpose built 100 MW HPC datacenter in Ellendale.&rdquo;




<h2>APLD Stock Movement Today</h2>



Investors aren&rsquo;t happy about these latest earnings results from Applied Digital. That has shares of APLD stock falling 5.5% as of Friday morning. That builds on a 55.9% decrease year-to-date as of Thursday&rsquo;s close.



With today&rsquo;s drop in price comes roughly 216,000 shares of APLD stock changing hands. That&rsquo;s well below its daily average trading volume of about 3.5 million shares.



Investors will find even more of the most recent stock market news below!



We have all of the hottest stock market stories worth reading about on Friday! That includes what&rsquo;s going on with shares of Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock, Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock this morning. All of that info is available at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-applied-digital-apld-stock-down-6-today/">Why Is Applied Digital (APLD) Stock Down 6% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Applied Digital (APLD) Stock Down 6% Today?

DCFC, HUSA and INDO among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) just reported results for the first quarter of 2024.<ul><li>PaxMedica reported earnings per share of -50 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/pxmd-stock-earnings-paxmedica-for-q1-of-2024/">PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024

PaxMedica files Nasdaq delisting appeal notice

ADIL

ALLR

APLD

BENF

BROG

CISS

DCFC

EZGO

GCTS

HGAS

HNRA

HUSA

INDO

KUKE

KZIA

LICY

LYEL

MDIA

MGRM

MOGU

MOTS

MRIN

NRXP

NXPL

PXMD

RENT

RLYB

SLNH

SNGX

SPEC

TPET

ZPTA

Health Care

Press Releases

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

PaxMedica Achieves Key Milestone in the Development of PAX-101  And Provides Update on Potential NDA Submission

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

General

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast

PaxMedica Provides Company Update and Continues to  Advance PAX-101 Regulatory Strategy

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

PaxMedica Secures Immediate Exercise of Warrants

PINKPXMD

HC Wainwright & Co.

Comments

PaxMedica

PaxMedica (PXMD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO